Wang Chen-Dong, Liu Run-Dong, Liu Ming-Jie, Song Jia
Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China.
Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China.
World J Gastrointest Surg. 2025 Mar 27;17(3):100951. doi: 10.4240/wjgs.v17.i3.100951.
Hepatocellular carcinoma (HCC) is a prevalent malignancy in China, primarily diagnosed at advanced stages, which limits treatment options and increases mortality rates. Conversion therapy, which includes systemic and locoregional treatments, aims to render unresectable tumors resectable. Nonetheless, research is scant on the risks of disease progression during the temporary cessation of targeted drugs and immune checkpoint inhibitors before surgery.
This report describes a 58-year-old male with HCC who developed lung metastases following the discontinuation of lenvatinib and tislelizumab, revealing the necessity for further investigation into the management of HCC patients during the perioperative period, particularly concerning the timing and duration of targeted therapy and immunotherapy.
Our study highlights the complex challenges in managing advanced HCC and emphasizes the critical need for ongoing research to refine treatment strategies and improve patient outcomes.
肝细胞癌（HCC）在中国是一种常见的恶性肿瘤，主要在晚期被诊断出来，这限制了治疗选择并增加了死亡率。转化治疗包括全身和局部治疗，旨在使不可切除的肿瘤变为可切除。然而，关于手术前暂时停用靶向药物和免疫检查点抑制剂期间疾病进展风险的研究很少。
本报告描述了一名58岁的HCC男性患者，在停用乐伐替尼和替雷利珠单抗后出现肺转移，这揭示了在围手术期进一步研究HCC患者管理的必要性，特别是关于靶向治疗和免疫治疗的时机和持续时间。
我们的研究突出了晚期HCC管理中的复杂挑战，并强调了持续开展研究以优化治疗策略和改善患者结局的迫切需求。
